Pfizer-BioNTech bivalent booster shows higher immune response, but new COVID cases climb back above 40,000 a day

Pfizer Inc. and Germany-based partner BioNTech said updated trial data for their omicron BA.4/BA.5-adapted bivalent booster showed a "substantially higher" immune response in adults than the original COVID-19 vaccine.